MEDICAMEN BIOTECH LIMITED

Manufactures and sells pharmaceutical products, with a focus on developing drug formulations for domestic and regulated overseas markets. The business raised Rs. 53.57 crore through a preferential issue in April 2025 to fund six stated objects: development of 50 drug SKUs for regulated markets, registration of dossiers, working capital, facility upgrades, domestic market expansion, and general corporate purposes; Rs. 29.30 crore had been utilised by March 31, 2026. Operates through subsidiaries Opal Pharmaceuticals and Medicamen Life Sciences, which contributed to consolidated nine-month PAT improving to about Rs. 531 lakh versus about Rs. 469 lakh in the prior-year period. In January 2026, the company received approval from the Danish Medicine Authority, in partnership with XGX Pharma Denmark, to register and market Paracetamol in Denmark under the EU regulatory framework. FY26 consolidated revenue stood at Rs. 197.77 crore with net profit of Rs. 9.80 crore and total assets of Rs. 371.99 crore, while materials at 47.7% of revenue and employee costs at 17.5% of revenue are the largest cost lines. The Board recommended a final dividend of Rs. 1 per equity share of Rs. 10 face value for FY26.